Clinical Trials
2
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome
- Conditions
- Angelman Syndrome
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Oak Hill Bio Ltd
- Registration Number
- NCT07136454
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Terminated
- Conditions
- Chronic Lung Disease of PrematurityBronchopulmonary DysplasiaRetinopathy of Prematurity (ROP)Intraventricular Hemorrhage
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Oak Hill Bio Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT04506619
- Locations
- 🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
News
No news found